Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-07-12
2011-07-12
Padmanabhan, Sreeni (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S403000, C514S468000
Reexamination Certificate
active
07977366
ABSTRACT:
The present invention relates to a method of treating an inflammatory disorder in a subject with an effective amount of compound having the general formula (I) as described in the present application, under conditions effective to treat the inflammatory disorder. The present invention also relates to a method of inhibiting respiratory burst in neutrophils without inhibiting degranulation in or bacterial killing by the neutrophils by contacting neutrophils with the compounds described above.
REFERENCES:
patent: 5462946 (1995-10-01), Mitchell et al.
patent: 5475017 (1995-12-01), Wuest et al.
patent: 2002/0119988 (2002-08-01), Sneddon et al.
patent: 2003/0073712 (2003-04-01), Wang et al.
patent: WO 2003024446 (2003-03-01), None
Ram et al.“Thieno[2,3-d]pyrimidines as Potential Chemotherapeutic Agents. II.”, J Het Chem, 1981, 18, 1227-1280.
http://www.medilexicon.com/medicaldictionary.php?t=13063.
Picciola et al., “Composti Eterociclici a Potenziale Attivita Antiinflammatoria Contenenti il Residuo di un Acido 4-Amminofenilalcanoico,”Farmaco39:371-378 (1984).
Short & Schoeb, “Synthesis and Structure of 5-Oxo-1-Phenylpyrazoline-3- and 4-Alkanoic Acids. Antiinflammatory Agents,”J. Heterocyclic Chem. 6:723-728 (1969).
International Search Report for PCT/US04/33914 (May 26, 2006).
Written Opinion for PCT/US2004/033914 (May 26, 2006).
Han et al., “Critical Role of the Carboxyl Terminus of Proline-Rich Tyrosine Kinase (Pyk2) in the Activation of Human Neutrophils by Tumor Necrosis Factor: Separation of Signals for the Respiratory Burst and Degranulation,” J. Exp. Med. 197(1):63-75 (2003).
Han et al., “Chemical Inhibitors of TNF Signal Transduction in Human Neutrophils Point to Distinct Steps in Cell Activation,” J. Leukoc. Biol. 79:147-154 (2006).
Han et al., “Calcium-Sensing Soluble Adenylyl Cyclase Mediates TNF Signal Transduction in Human Neutrophils,” J. Exp. Med. 202(3):353-361 (2005).
Han, “Tumor Necrosis Factor Triggered Signaling Cascades in Adherent Human Neutrophils: Separation of Signals for the Respiratory Burst and Degranulation,” Dissertation Presented to the Faculty of the Joan and Sanford I. Weill Graduate School of Biomedical Sciences of Cornell University (Indexed Feb. 2004).
Parsons, “Focal Adhesion Kinase: The First Ten Years,” J. Cell Sci. 116:1409-1416 (2003).
Sadhu et al., “Essential Role of Phosphoinositide 3-Kinase Delta in Neutrophil Directional Movement,” J. Immunol. 170:2647-2654 (2003).
Nathan, “Inflammation as a Flow of Information,” Oral Presentation, Weill Medical College, Cornell University (Oct. 15, 2003).
Han Hyunsil
Lin Gang
Nathan Carl
Cornell Research Foundation Inc.
Javanmard Sahar
LeClairRyan
Padmanabhan Sreeni
LandOfFree
Treating an inflammatory disorder or inhibiting respiratory... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treating an inflammatory disorder or inhibiting respiratory..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treating an inflammatory disorder or inhibiting respiratory... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2650337